Day One Biopharmaceuticals (NASDAQ:DAWN) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN) posted its quarterly earnings data on Tuesday. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04), FiscalAI reports. The company had revenue of $53.72 million for the quarter, compared to the consensus estimate of $49.81 million. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%.

Here are the key takeaways from Day One Biopharmaceuticals’ conference call:

• OJEMDA commercial traction: 2025 net product revenue was $155.4M (up 172% YoY) with Q4 revenue of $52.8M and >4,600 prescriptions; management reiterated 2026 OJEMDA guidance of $225M–$250M.
• Three‑year FIREFLY‑1 data strengthen clinical case: company reports a 53% objective response rate, median response duration ~19.4 months, no new safety signals, and a median time‑to‑next‑treatment (TTNT) of 42.6 months versus a 16.6‑month PFS, which management says supports durable clinical benefit.
• Pipeline and BD progress: acquisition of Mersana closed in January to add Emi‑Le (early activity in adenoid cystic carcinoma) with an updated dataset planned for mid‑2026 and potential accelerated development, plus DAY301 early signals expected H2 2026.
• Concentration and timing risks remain: Day One is heavily dependent on OJEMDA as its primary revenue driver and future performance hinges on persistence, new patient starts, payer dynamics, and successful enrollment/readout of FIREFLY‑2 (top‑line mid‑2027); statements are forward‑looking and company‑presented.

Day One Biopharmaceuticals Price Performance

NASDAQ:DAWN traded down $1.08 during midday trading on Wednesday, reaching $10.94. 2,146,809 shares of the company traded hands, compared to its average volume of 2,451,042. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -7.20 and a beta of -1.26. The company has a fifty day moving average price of $10.63 and a 200 day moving average price of $8.74. Day One Biopharmaceuticals has a twelve month low of $5.64 and a twelve month high of $13.20.

More Day One Biopharmaceuticals News

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Record revenue and reaffirmed 2026 outlook — Day One reported Q4 product revenue of ~$52.8M and full‑year 2025 net product revenue of $155.4M, beating consensus. Management reaffirmed 2026 U.S. net product revenue guidance of $225–$250M, which supports growth expectations. Press Release
• Positive Sentiment: Pipeline expansion via acquisition — The company completed the January acquisition of Mersana, adding Emi‑Le (Phase 1 for ACC) and expanding oncology pipeline optionality, a longer‑term positive for valuation if assets advance. Press Release
• Positive Sentiment: Wedbush raises price target — Wedbush bumped its PT from $29 to $30 and maintained an “outperform” call, implying meaningful upside versus current levels and giving bullish third‑party validation. Benzinga TickerReport
• Neutral Sentiment: Earnings materials and call transcripts available — Full Q4 slide deck and earnings‑call transcripts were posted (useful for digging into unit trends, OJEMDA uptake, and margin drivers). These provide detail but are not immediately price‑moving by themselves. Slide Deck Presentation
• Negative Sentiment: EPS miss and margins remain a concern — Reported EPS of ($0.21) missed the ($0.17) consensus and the company still shows negative net margin and ROE, fueling near‑term disappointment and selling pressure despite the revenue beat. MarketBeat
• Negative Sentiment: Mixed analyst reactions — While some firms raised targets, Needham cut its PT to $17 and HC Wainwright trimmed to $22 (both kept “buy”), reflecting differing views on near‑term profitability and risk; the cuts add downward pressure even as other shops remain constructive. Benzinga

Insider Buying and Selling

In other news, CEO Jeremy Bender sold 15,459 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $179,324.40. Following the completion of the transaction, the chief executive officer owned 204,603 shares of the company’s stock, valued at approximately $2,373,394.80. The trade was a 7.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Lauren Merendino sold 5,814 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $67,442.40. Following the completion of the sale, the insider directly owned 60,157 shares in the company, valued at approximately $697,821.20. This trade represents a 8.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 36,461 shares of company stock valued at $422,948 in the last three months. 6.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Hedge funds have recently made changes to their positions in the business. Invesco Ltd. grew its holdings in Day One Biopharmaceuticals by 26.5% in the 4th quarter. Invesco Ltd. now owns 123,994 shares of the company’s stock worth $1,156,000 after buying an additional 25,952 shares in the last quarter. Oracle Investment Management Inc. acquired a new position in Day One Biopharmaceuticals during the 4th quarter worth $932,000. XTX Topco Ltd grew its stake in shares of Day One Biopharmaceuticals by 62.9% in the fourth quarter. XTX Topco Ltd now owns 128,440 shares of the company’s stock worth $1,197,000 after purchasing an additional 49,592 shares in the last quarter. VARCOV Co. acquired a new position in shares of Day One Biopharmaceuticals during the fourth quarter valued at $261,000. Finally, Vestal Point Capital LP raised its stake in shares of Day One Biopharmaceuticals by 94.4% during the fourth quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock valued at $48,464,000 after purchasing an additional 2,525,000 shares in the last quarter. Institutional investors own 87.95% of the company’s stock.

Analyst Ratings Changes

DAWN has been the topic of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a research note on Monday, December 29th. Zacks Research raised Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 26th. JPMorgan Chase & Co. lifted their target price on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Wedbush raised their price objective on Day One Biopharmaceuticals from $29.00 to $30.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Needham & Company LLC lowered their target price on shares of Day One Biopharmaceuticals from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $26.14.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.